Johnson & Johnson (JNJ)

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Symbol
JNJ
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$632.66B
52 week range
182.94 - 281.07

Valuation

Share price
$258.66 (close of 2026-10-01)
P/E (TTM)
30.10x
Price to book
7.45x
Price to free cash flow
28.44x
Enterprise value
$660.94B
Book value per share
$35.30

Price performance

PeriodChange
1 day-2.30%
5 days-4.44%
1 month-4.62%
3 months+1.84%
6 months+5.96%
Year to date+24.99%
1 year+39.03%
3 years+66.07%
5 years+61.19%
10 years+118.96%
All time+21101.64%

Members of Congress who disclosed JNJ trades

Thomas Kean · Josh Gottheimer · Lisa McClain · Lloyd Doggett · Richard McCormick · Gilbert Ray Cisneros · Julie Johnson · Marjorie Taylor Greene · Jefferson Shreve · Alan Armstrong · Bruce Westerman · Jared Moskowitz

And 12 others

Super investors holding JNJ

Yacktman Asset Mgmt (Yacktman Asset Management LP) · Ray Dalio (Bridgewater Associates) · Tweedy Browne (Tweedy Browne Company LLC) · Prem Watsa (Fairfax Financial Holdings)

Profitability and growth

Return on equity
32.87%
Return on assets
13.46%
Gross margin
67.88%
Net margin
28.46%
EBITDA margin
42.56%
Revenue growth
6.05%
Net income growth
90.56%
Free cash flow growth
-0.73%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.52%
Current ratio
1.09x
Net debt to EBITDA
0.83x

Latest reported year

Period end
2025-12-28
Fiscal year
2025
Revenue
$94.19B
Cost of revenue
$30.26B
Gross profit
$63.94B
EBITDA
$40.08B
Net income
$26.80B
Earnings per share
$11.13
Research and development
$109.00M
Shares outstanding
2.41B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-28$94.19B$63.94B$26.80B$11.13
2024-12-29$88.82B$61.35B$14.07B$5.84
2023-12-31$85.16B$58.61B$35.15B$13.88
2023-01-01$79.99B$55.39B$17.94B$6.83
2022-01-02$78.74B$55.34B$20.88B$7.93
2021-01-03$82.58B$54.16B$14.71B$5.59
2019-12-29$82.06B$54.50B$15.12B$5.72
2018-12-30$81.58B$54.49B$15.30B$5.70
2017-12-31$76.45B$51.01B$1.30B$0.48
2017-01-01$71.89B$50.10B$16.54B$6.04

Margins and returns by year

Period endGross marginNet marginReturn on equity
2025-12-2867.88%28.46%32.87%
2024-12-2969.07%15.84%19.68%
2023-12-3168.82%41.28%51.11%
2023-01-0169.25%22.43%23.36%
2022-01-0270.28%26.52%28.20%
2021-01-0365.58%17.82%23.25%
2019-12-2966.42%18.42%25.42%
2018-12-3066.79%18.75%25.60%
2017-12-3166.72%1.70%2.16%
2017-01-0169.69%23.01%23.49%

Cash and debt by year

Period endCashDebt
2025-12-28$19.71B$39.44B
2024-12-29$24.11B$30.65B
2023-12-31$21.86B$25.88B
2023-01-01$12.89B$26.89B
2022-01-02$14.49B$29.98B
2021-01-03$25.18B$32.63B
2019-12-29$19.29B$26.49B
2018-12-30$19.69B$27.68B
2017-12-31$18.30B$30.68B
2017-01-01$41.91B$22.44B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-28$19.70B$1.35B
2024-12-29$19.84B$1.18B
2023-12-31$18.25B$1.16B
2023-01-01$17.18B$1.14B
2022-01-02$19.76B$1.14B
2021-01-03$20.19B$1.00B
2019-12-29$19.92B$977.00M
2018-12-30$18.53B$978.00M
2017-12-31$17.78B$962.00M
2017-01-01$15.54B$878.00M

Dividend history

Most recent payment
2026-08-25
Paid in the last twelve months
$5.28
Payment dateDividend per share
2026-08-25$1.34
2026-05-26$1.34
2026-02-24$1.30
2025-11-25$1.30
2025-08-26$1.30
2025-05-27$1.30
2025-02-18$1.24
2024-11-26$1.24

Investor relations

Next earnings report

Next confirmed report
2026-10-13
Consensus EPS estimate
$2.90

Past earnings dates

ReportedFiscal periodEPS estimate
2026-07-15Jun/2026$2.84
2026-04-14--
2026-01-21--
2025-10-14--
2025-07-16--
2025-04-15--
2025-01-22--
2024-10-15--

Filings and sources

Company website
jnj.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

AbbVie Inc. (ABBV) · Eli Lilly & Co (LLY) · Merck & Co., Inc. (MRK) · Novartis AG (NVS) · AstraZeneca plc (AZN) · ICON plc (ICLR) · Charles River Laboratories International, Inc. (CRL) · Revvity, Inc. (RVTY)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades